Compare Norfolk Southern Corporation (NSC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs TG Therapeutics Inc — how do they compare? Norfolk Southern Corporation trades at $323.3 (market cap $73.65B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Norfolk Southern Corporation is far larger — about 8.6× TG Therapeutics Inc's market cap, and Norfolk Southern Corporation pays a 1.65% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NSC | TGTX | |
|---|---|---|
Market Cap | $73.65B | $8.53B |
Sector | Technology | Health |
52-Week High | $352.98 | $59.06 |
52-Week Low | $272.36 | $26.94 |
Enterprise Value | $89.20B | $8.74B |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $327.92, down 0.47% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Key fundamentals show strong profitability with a 21.02% net income margin and 16.97% ROE, though valuation multiples like the P/E of 27.98 appear elevated. Recent news highlights ongoing institutional accumulation and progress in the proposed merger with Union Pacific, which remains under regulatory review.
The outlook is balanced; the merger potential offers upside, but regulatory hurdles and a premium valuation pose risks. Analyst consensus is mixed with a Hold rating predominating, though the $369.67 price target implies modest upside. Earnings sustainability and merger approval are critical for near-term direction.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
